MedTrace Logo

A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee

NCT03231280 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-04-19

No results posted yet for this study

Summary

This study evaluates a novel agent, SB-061, for the treatment of osteoarthritis of the knee. Half of the patients will receive the agent via intra-articular injection and half will receive a placebo injection.

Conditions

Interventions

DEVICE

SB-061

delivered via intra-articular injection

OTHER

Placebo

Placebo delivered via intra-articular injection

Sponsors & Collaborators

  • Nordic Bioscience A/S

    collaborator INDUSTRY

  • Symic OA Co.

    lead INDUSTRY

Principal Investigators

  • Nathan Bachtell, MD · Symic OA Co.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2017-12-18
Completion
2018-03-27

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03231280 on ClinicalTrials.gov